| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 49 | 2024 | 2565 | 3.030 |
Why?
|
| Osteosarcoma | 22 | 2024 | 911 | 2.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 55 | 2023 | 11854 | 1.440 |
Why?
|
| Neuroectodermal Tumors, Primitive | 10 | 2007 | 137 | 1.180 |
Why?
|
| Ifosfamide | 21 | 2023 | 234 | 1.100 |
Why?
|
| Etoposide | 16 | 2023 | 639 | 0.660 |
Why?
|
| Rhabdomyosarcoma | 10 | 2018 | 358 | 0.640 |
Why?
|
| Vincristine | 21 | 2023 | 1040 | 0.630 |
Why?
|
| Soft Tissue Neoplasms | 9 | 2009 | 1167 | 0.530 |
Why?
|
| Doxorubicin | 24 | 2023 | 2229 | 0.510 |
Why?
|
| Cyclophosphamide | 17 | 2021 | 2226 | 0.450 |
Why?
|
| Fibrosarcoma | 6 | 2002 | 313 | 0.450 |
Why?
|
| Cisplatin | 11 | 2019 | 1661 | 0.440 |
Why?
|
| Child | 113 | 2024 | 80891 | 0.400 |
Why?
|
| Dactinomycin | 13 | 2009 | 305 | 0.390 |
Why?
|
| Child, Preschool | 78 | 2021 | 42650 | 0.370 |
Why?
|
| Disease-Free Survival | 21 | 2017 | 6856 | 0.360 |
Why?
|
| Sarcoma | 11 | 2009 | 1807 | 0.350 |
Why?
|
| Translocation, Genetic | 7 | 2009 | 1395 | 0.330 |
Why?
|
| Adolescent | 89 | 2021 | 89184 | 0.320 |
Why?
|
| Fibromatosis, Aggressive | 3 | 2012 | 125 | 0.300 |
Why?
|
| Infant | 63 | 2021 | 36510 | 0.300 |
Why?
|
| Laryngeal Neoplasms | 2 | 2009 | 515 | 0.300 |
Why?
|
| Nose Neoplasms | 1 | 2009 | 250 | 0.280 |
Why?
|
| Topotecan | 4 | 2021 | 131 | 0.270 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 259 | 0.260 |
Why?
|
| Neuroblastoma | 9 | 2003 | 1266 | 0.260 |
Why?
|
| Survival Rate | 22 | 2019 | 12870 | 0.260 |
Why?
|
| Neoplasms, Second Primary | 3 | 2010 | 1060 | 0.260 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 2005 | 19 | 0.250 |
Why?
|
| Combined Modality Therapy | 21 | 2022 | 8562 | 0.240 |
Why?
|
| Hearing Loss | 2 | 2010 | 786 | 0.240 |
Why?
|
| Lymphocyte Count | 1 | 2007 | 793 | 0.240 |
Why?
|
| Methotrexate | 10 | 2019 | 1722 | 0.240 |
Why?
|
| Thoracic Neoplasms | 3 | 1994 | 269 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2022 | 9433 | 0.210 |
Why?
|
| Attitude to Death | 3 | 2007 | 401 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 5 | 2019 | 2909 | 0.200 |
Why?
|
| Testis | 6 | 2014 | 783 | 0.200 |
Why?
|
| Truth Disclosure | 5 | 2016 | 433 | 0.190 |
Why?
|
| Retroperitoneal Space | 1 | 2001 | 173 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2022 | 250 | 0.180 |
Why?
|
| Pelvic Bones | 2 | 2017 | 274 | 0.180 |
Why?
|
| Antineoplastic Agents | 12 | 2011 | 13697 | 0.180 |
Why?
|
| Neoplasms | 22 | 2016 | 22385 | 0.180 |
Why?
|
| Male | 99 | 2021 | 364902 | 0.180 |
Why?
|
| Humans | 147 | 2024 | 768393 | 0.180 |
Why?
|
| Mesna | 3 | 2005 | 62 | 0.170 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2020 | 101 | 0.170 |
Why?
|
| Neoplasm Metastasis | 9 | 2019 | 4921 | 0.170 |
Why?
|
| Drug Administration Schedule | 13 | 2012 | 4859 | 0.170 |
Why?
|
| Ribs | 2 | 2003 | 259 | 0.170 |
Why?
|
| Female | 93 | 2021 | 397089 | 0.160 |
Why?
|
| Prognosis | 25 | 2022 | 30022 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 1995 | 3620 | 0.150 |
Why?
|
| Carboplatin | 1 | 2001 | 799 | 0.150 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 3 | 1994 | 43 | 0.150 |
Why?
|
| Neuroectodermal Tumors | 1 | 1997 | 23 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2016 | 3553 | 0.140 |
Why?
|
| Cytarabine | 6 | 2009 | 697 | 0.140 |
Why?
|
| Treatment Outcome | 30 | 2016 | 65379 | 0.140 |
Why?
|
| Parents | 6 | 2011 | 3596 | 0.140 |
Why?
|
| Urogenital Neoplasms | 1 | 2018 | 133 | 0.140 |
Why?
|
| Tissue Banks | 1 | 2017 | 184 | 0.130 |
Why?
|
| Palliative Care | 7 | 2008 | 3643 | 0.130 |
Why?
|
| Spermatogenesis | 4 | 2014 | 259 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2009 | 4069 | 0.130 |
Why?
|
| Forearm | 1 | 1998 | 428 | 0.130 |
Why?
|
| Lymph Node Excision | 2 | 2001 | 1274 | 0.130 |
Why?
|
| Adult | 56 | 2019 | 223640 | 0.120 |
Why?
|
| Receptors, Cell Surface | 3 | 2015 | 2819 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 15 | 3 | 2009 | 361 | 0.120 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 11254 | 0.120 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 39407 | 0.120 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2015 | 38 | 0.120 |
Why?
|
| Communication | 6 | 2016 | 3912 | 0.120 |
Why?
|
| Bone Marrow | 4 | 2020 | 2929 | 0.110 |
Why?
|
| Smegmamorpha | 2 | 2003 | 14 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 640 | 0.110 |
Why?
|
| Rhabdomyoma | 1 | 2013 | 56 | 0.110 |
Why?
|
| Parotid Neoplasms | 2 | 2006 | 158 | 0.110 |
Why?
|
| Receptor, erbB-2 | 3 | 2014 | 2588 | 0.110 |
Why?
|
| Hedgehog Proteins | 2 | 2018 | 770 | 0.100 |
Why?
|
| Terminal Care | 6 | 2005 | 1773 | 0.100 |
Why?
|
| ras Proteins | 1 | 2018 | 1058 | 0.100 |
Why?
|
| Alkylating Agents | 1 | 1993 | 132 | 0.100 |
Why?
|
| Cardiotonic Agents | 1 | 2015 | 544 | 0.100 |
Why?
|
| Barbiturates | 1 | 1992 | 113 | 0.100 |
Why?
|
| Muscle Neoplasms | 1 | 2013 | 130 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2019 | 1794 | 0.100 |
Why?
|
| Ovary | 2 | 2009 | 960 | 0.100 |
Why?
|
| Extremities | 1 | 2017 | 870 | 0.100 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 393 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 6541 | 0.090 |
Why?
|
| Infant, Newborn | 18 | 2021 | 26411 | 0.090 |
Why?
|
| Celiac Plexus | 1 | 1990 | 34 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2005 | 631 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2013 | 2524 | 0.090 |
Why?
|
| Aftercare | 1 | 2016 | 921 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1990 | 38 | 0.090 |
Why?
|
| Morphine | 4 | 1996 | 658 | 0.090 |
Why?
|
| Professional-Family Relations | 3 | 2011 | 501 | 0.080 |
Why?
|
| Epiglottis | 1 | 2009 | 81 | 0.080 |
Why?
|
| Existentialism | 1 | 2009 | 38 | 0.080 |
Why?
|
| Antidotes | 1 | 2010 | 138 | 0.080 |
Why?
|
| Mercaptoethanol | 1 | 1989 | 61 | 0.080 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2010 | 117 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2009 | 20765 | 0.080 |
Why?
|
| Pain | 6 | 2005 | 5103 | 0.080 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2000 | 99 | 0.080 |
Why?
|
| Survival Analysis | 7 | 2005 | 10117 | 0.080 |
Why?
|
| Retrospective Studies | 23 | 2022 | 81801 | 0.080 |
Why?
|
| Medical Oncology | 3 | 2010 | 2349 | 0.080 |
Why?
|
| Prednisolone | 5 | 1992 | 327 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2009 | 350 | 0.080 |
Why?
|
| Leukemia, Myeloid | 2 | 2006 | 693 | 0.080 |
Why?
|
| Remission Induction | 8 | 2004 | 2407 | 0.080 |
Why?
|
| Academies and Institutes | 1 | 2010 | 326 | 0.070 |
Why?
|
| Glottis | 1 | 2009 | 214 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2016 | 1913 | 0.070 |
Why?
|
| Lipoma | 1 | 2010 | 296 | 0.070 |
Why?
|
| Parent-Child Relations | 3 | 2007 | 774 | 0.070 |
Why?
|
| Liver Neoplasms | 7 | 1998 | 4365 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 362 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2017 | 2663 | 0.070 |
Why?
|
| Recurrence | 6 | 2008 | 8506 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 2010 | 424 | 0.070 |
Why?
|
| Hematuria | 1 | 1989 | 233 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2002 | 2226 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2010 | 289 | 0.070 |
Why?
|
| Lung Neoplasms | 5 | 2019 | 13576 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 2018 | 2923 | 0.070 |
Why?
|
| Hermaphroditic Organisms | 2 | 2003 | 7 | 0.070 |
Why?
|
| Hematology | 1 | 2010 | 244 | 0.070 |
Why?
|
| Axilla | 1 | 2009 | 628 | 0.070 |
Why?
|
| Monosomy | 1 | 1986 | 52 | 0.070 |
Why?
|
| Spinal Neoplasms | 2 | 2009 | 716 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 1998 | 431 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2009 | 379 | 0.070 |
Why?
|
| Menarche | 1 | 2009 | 538 | 0.070 |
Why?
|
| Culture | 2 | 2009 | 623 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2019 | 5713 | 0.070 |
Why?
|
| Puberty | 1 | 2009 | 502 | 0.070 |
Why?
|
| Sex Determination Processes | 2 | 2003 | 61 | 0.070 |
Why?
|
| Amifostine | 1 | 2006 | 40 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 687 | 0.070 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 255 | 0.060 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2010 | 302 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1986 | 310 | 0.060 |
Why?
|
| Cohort Studies | 7 | 2019 | 41795 | 0.060 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2006 | 91 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 1997 | 411 | 0.060 |
Why?
|
| Disease Progression | 6 | 2019 | 13646 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 1998 | 2336 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2016 | 2529 | 0.060 |
Why?
|
| Time Factors | 9 | 2019 | 40272 | 0.060 |
Why?
|
| Physician-Patient Relations | 3 | 2007 | 3267 | 0.060 |
Why?
|
| Pyrroles | 1 | 2011 | 1126 | 0.060 |
Why?
|
| Nerve Block | 2 | 1996 | 716 | 0.060 |
Why?
|
| Hospitals, Pediatric | 3 | 2010 | 1876 | 0.060 |
Why?
|
| Eye Neoplasms | 1 | 1986 | 306 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2017 | 8075 | 0.060 |
Why?
|
| Spirituality | 1 | 2009 | 430 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 1997 | 348 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 12092 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 2006 | 255 | 0.060 |
Why?
|
| DNA, Neoplasm | 4 | 2013 | 1748 | 0.060 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 957 | 0.060 |
Why?
|
| Protective Agents | 1 | 2005 | 150 | 0.060 |
Why?
|
| Camptothecin | 2 | 1998 | 593 | 0.060 |
Why?
|
| Retinoblastoma | 1 | 1986 | 321 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2017 | 6277 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 1145 | 0.050 |
Why?
|
| Gene Amplification | 4 | 1993 | 1090 | 0.050 |
Why?
|
| Boston | 7 | 2010 | 9371 | 0.050 |
Why?
|
| Neutropenia | 3 | 2011 | 893 | 0.050 |
Why?
|
| Cross-Cultural Comparison | 1 | 2007 | 638 | 0.050 |
Why?
|
| Infertility | 1 | 2010 | 655 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2016 | 3476 | 0.050 |
Why?
|
| Transplantation, Autologous | 3 | 2019 | 2127 | 0.050 |
Why?
|
| Cervical Vertebrae | 1 | 2009 | 982 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1825 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2003 | 326 | 0.050 |
Why?
|
| Decision Making | 2 | 2011 | 3953 | 0.050 |
Why?
|
| Vinblastine | 2 | 2007 | 488 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2018 | 1614 | 0.050 |
Why?
|
| Chromosome Aberrations | 4 | 1994 | 1780 | 0.050 |
Why?
|
| Genes, myc | 3 | 1993 | 391 | 0.050 |
Why?
|
| Review Literature as Topic | 2 | 2015 | 353 | 0.050 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 263 | 0.050 |
Why?
|
| Giant Cell Tumors | 1 | 2002 | 89 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 1986 | 1390 | 0.050 |
Why?
|
| Prospective Studies | 9 | 2016 | 54920 | 0.050 |
Why?
|
| Biopsy | 3 | 2024 | 6808 | 0.050 |
Why?
|
| Oncogenes | 3 | 2003 | 1235 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 3 | 1996 | 3407 | 0.050 |
Why?
|
| Receptors, Estrogen | 2 | 2008 | 2247 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3464 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2010 | 1133 | 0.050 |
Why?
|
| Hemangioblastoma | 1 | 2002 | 62 | 0.050 |
Why?
|
| Pulmonary Blastoma | 1 | 2001 | 43 | 0.050 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2003 | 243 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 1995 | 8051 | 0.050 |
Why?
|
| Uterine Rupture | 1 | 2001 | 66 | 0.050 |
Why?
|
| Azacitidine | 2 | 1993 | 336 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2010 | 2952 | 0.050 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2003 | 290 | 0.050 |
Why?
|
| Young Adult | 10 | 2019 | 60049 | 0.050 |
Why?
|
| Genitalia, Male | 1 | 2001 | 87 | 0.050 |
Why?
|
| Whole-Body Irradiation | 1 | 2001 | 435 | 0.050 |
Why?
|
| Sacrum | 1 | 2022 | 275 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 1999 | 1727 | 0.040 |
Why?
|
| Daunorubicin | 3 | 1990 | 157 | 0.040 |
Why?
|
| Radiography | 2 | 2009 | 6993 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2009 | 1885 | 0.040 |
Why?
|
| Analgesia | 2 | 1995 | 460 | 0.040 |
Why?
|
| Survivors | 1 | 2010 | 2382 | 0.040 |
Why?
|
| Karyotyping | 5 | 1998 | 1173 | 0.040 |
Why?
|
| Luteinizing Hormone | 3 | 2014 | 821 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2010 | 2103 | 0.040 |
Why?
|
| Artificial Gene Fusion | 1 | 1998 | 56 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 2 | 1993 | 403 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 10377 | 0.040 |
Why?
|
| Nephroma, Mesoblastic | 1 | 1998 | 25 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2025 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 718 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2009 | 4303 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 2663 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 2412 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2011 | 3587 | 0.040 |
Why?
|
| Stem Cells | 1 | 2011 | 3539 | 0.040 |
Why?
|
| Placenta Accreta | 1 | 2001 | 241 | 0.040 |
Why?
|
| Hepatoblastoma | 1 | 1998 | 90 | 0.040 |
Why?
|
| Infertility, Male | 1 | 2001 | 397 | 0.040 |
Why?
|
| Uterus | 1 | 2001 | 661 | 0.040 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1998 | 200 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2002 | 910 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2007 | 646 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2017 | 68 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 4120 | 0.040 |
Why?
|
| Paired Box Transcription Factors | 1 | 2018 | 206 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2011 | 5336 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 1034 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2018 | 195 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 618 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 10776 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2016 | 1558 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2010 | 2819 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2020 | 2056 | 0.030 |
Why?
|
| Leukemia | 1 | 1985 | 1526 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 1993 | 736 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1986 | 1399 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 2001 | 612 | 0.030 |
Why?
|
| Hydromorphone | 1 | 1996 | 70 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1996 | 117 | 0.030 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2017 | 303 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1998 | 453 | 0.030 |
Why?
|
| Endodermal Sinus Tumor | 1 | 1996 | 53 | 0.030 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1999 | 335 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2003 | 2060 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2016 | 235 | 0.030 |
Why?
|
| Pediatrics | 1 | 2010 | 3624 | 0.030 |
Why?
|
| Thrombocytopenia | 2 | 2002 | 1180 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 3 | 1995 | 2709 | 0.030 |
Why?
|
| Muscles | 2 | 2018 | 1582 | 0.030 |
Why?
|
| Pain, Intractable | 1 | 1996 | 132 | 0.030 |
Why?
|
| Periaqueductal Gray | 1 | 1995 | 111 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2001 | 805 | 0.030 |
Why?
|
| Critical Care | 1 | 2007 | 2716 | 0.030 |
Why?
|
| Consensus | 1 | 2024 | 3212 | 0.030 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 144 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 753 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2017 | 384 | 0.030 |
Why?
|
| Mutation | 2 | 2018 | 30228 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2001 | 1204 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 462 | 0.030 |
Why?
|
| Pneumonectomy | 2 | 2019 | 1158 | 0.030 |
Why?
|
| Mesencephalon | 1 | 1995 | 339 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 384 | 0.030 |
Why?
|
| Rhabdoid Tumor | 1 | 1995 | 211 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 594 | 0.030 |
Why?
|
| Risk Factors | 5 | 2019 | 74962 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2009 | 36849 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 5 | 2003 | 6132 | 0.030 |
Why?
|
| Sulindac | 1 | 2012 | 29 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 1996 | 659 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 1998 | 1019 | 0.030 |
Why?
|
| Isoxazoles | 1 | 1995 | 233 | 0.030 |
Why?
|
| Stress, Psychological | 3 | 2008 | 4543 | 0.030 |
Why?
|
| Family | 3 | 2016 | 3208 | 0.030 |
Why?
|
| Anesthesia, Conduction | 1 | 1996 | 263 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 3439 | 0.030 |
Why?
|
| Quality of Health Care | 2 | 2005 | 4339 | 0.030 |
Why?
|
| Hamartoma | 1 | 1994 | 236 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2001 | 2258 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2011 | 4031 | 0.020 |
Why?
|
| Analgesics, Opioid | 3 | 1996 | 3836 | 0.020 |
Why?
|
| Carcinoma | 1 | 2003 | 2341 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1998 | 1628 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 1705 | 0.020 |
Why?
|
| Mesenchymoma | 1 | 1991 | 50 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 1992 | 408 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 1991 | 127 | 0.020 |
Why?
|
| Analgesia, Epidural | 2 | 1996 | 332 | 0.020 |
Why?
|
| Genital Neoplasms, Male | 1 | 1990 | 68 | 0.020 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1992 | 263 | 0.020 |
Why?
|
| Ventilators, Mechanical | 1 | 1992 | 292 | 0.020 |
Why?
|
| Age Factors | 4 | 2015 | 18471 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 1992 | 387 | 0.020 |
Why?
|
| Women's Health Services | 1 | 2010 | 88 | 0.020 |
Why?
|
| Cell Separation | 1 | 1996 | 1726 | 0.020 |
Why?
|
| Risk | 3 | 2006 | 9636 | 0.020 |
Why?
|
| SEER Program | 1 | 2015 | 1474 | 0.020 |
Why?
|
| Iohexol | 1 | 1990 | 205 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1991 | 313 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 2007 | 1379 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1991 | 594 | 0.020 |
Why?
|
| Femur | 1 | 2016 | 1311 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2003 | 4936 | 0.020 |
Why?
|
| Life Tables | 1 | 1990 | 368 | 0.020 |
Why?
|
| Pregnancy | 3 | 2008 | 30200 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1994 | 708 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2010 | 236 | 0.020 |
Why?
|
| Physicians | 5 | 2007 | 4614 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1994 | 1627 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 2066 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 890 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 1998 | 8634 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 2 | 1995 | 1188 | 0.020 |
Why?
|
| Registries | 2 | 2002 | 8379 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2012 | 968 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1992 | 780 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 5800 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1993 | 916 | 0.020 |
Why?
|
| Testosterone | 2 | 2014 | 2493 | 0.020 |
Why?
|
| Menstruation | 1 | 2009 | 310 | 0.020 |
Why?
|
| Reoperation | 1 | 1998 | 4341 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 1614 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 1998 | 2986 | 0.020 |
Why?
|
| Middle Aged | 8 | 2019 | 223491 | 0.020 |
Why?
|
| Brachytherapy | 1 | 1995 | 1226 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1992 | 785 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 12558 | 0.020 |
Why?
|
| RNA | 1 | 2017 | 2726 | 0.020 |
Why?
|
| Bupivacaine | 1 | 1990 | 412 | 0.020 |
Why?
|
| Genetic Markers | 2 | 1998 | 2604 | 0.020 |
Why?
|
| Bibliometrics | 1 | 2010 | 355 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2001 | 726 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 1986 | 351 | 0.020 |
Why?
|
| Data Collection | 2 | 2009 | 3324 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2009 | 1018 | 0.020 |
Why?
|
| Attitude | 1 | 2011 | 772 | 0.020 |
Why?
|
| Resuscitation Orders | 1 | 2008 | 271 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2013 | 2673 | 0.020 |
Why?
|
| Research Personnel | 1 | 2010 | 590 | 0.020 |
Why?
|
| Health Care Surveys | 2 | 2005 | 2437 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 1837 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 3543 | 0.020 |
Why?
|
| Ultrasonography, Prenatal | 1 | 1993 | 1767 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 1255 | 0.020 |
Why?
|
| Lung Diseases, Fungal | 1 | 1985 | 124 | 0.020 |
Why?
|
| Nervous System Neoplasms | 1 | 1985 | 91 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 2003 | 2559 | 0.010 |
Why?
|
| Amino Acid Sequence | 3 | 2003 | 13423 | 0.010 |
Why?
|
| Perception | 1 | 2011 | 1205 | 0.010 |
Why?
|
| Emotions | 1 | 2016 | 2768 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1994 | 1925 | 0.010 |
Why?
|
| Chromosomes, Human, 19-20 | 1 | 2003 | 11 | 0.010 |
Why?
|
| Trust | 1 | 2009 | 532 | 0.010 |
Why?
|
| Ethanol | 1 | 1990 | 1332 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 1004 | 0.010 |
Why?
|
| Chromosomes, Human, 13-15 | 1 | 2003 | 49 | 0.010 |
Why?
|
| Quality of Life | 4 | 2009 | 13503 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1995 | 3722 | 0.010 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2003 | 9 | 0.010 |
Why?
|
| Sertoli Cells | 1 | 2003 | 50 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1987 | 1605 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 1990 | 1131 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1994 | 3712 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 15455 | 0.010 |
Why?
|
| Transcription Factors | 2 | 2003 | 12166 | 0.010 |
Why?
|
| Myeloablative Agonists | 1 | 2003 | 210 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 622 | 0.010 |
Why?
|
| Immunohistochemistry | 4 | 2003 | 11120 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 250 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 2 | 2003 | 2635 | 0.010 |
Why?
|
| United States | 4 | 2007 | 73150 | 0.010 |
Why?
|
| Japan | 1 | 2007 | 1418 | 0.010 |
Why?
|
| Pedigree | 1 | 2010 | 4544 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 2004 | 6241 | 0.010 |
Why?
|
| Palatal Neoplasms | 1 | 2002 | 37 | 0.010 |
Why?
|
| Bleomycin | 1 | 2003 | 493 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 2010 | 1218 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 1885 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1998 | 9614 | 0.010 |
Why?
|
| Granulocytes | 1 | 1983 | 550 | 0.010 |
Why?
|
| Leucovorin | 1 | 2003 | 643 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 599 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2003 | 946 | 0.010 |
Why?
|
| Models, Biological | 1 | 2017 | 9493 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1991 | 2846 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9562 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1985 | 1616 | 0.010 |
Why?
|
| Acute Disease | 2 | 2006 | 7242 | 0.010 |
Why?
|
| Gene Expression | 1 | 2013 | 7598 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2017 | 7880 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5900 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11668 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1996 | 1595 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 595 | 0.010 |
Why?
|
| Psychometrics | 1 | 2009 | 3069 | 0.010 |
Why?
|
| Anorexia | 1 | 2000 | 152 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1992 | 642 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2000 | 132 | 0.010 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1999 | 43 | 0.010 |
Why?
|
| Motivation | 1 | 2009 | 2029 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2004 | 1337 | 0.010 |
Why?
|
| Receptor, trkC | 1 | 1998 | 63 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 1998 | 64 | 0.010 |
Why?
|
| Epithelium | 1 | 2003 | 1609 | 0.010 |
Why?
|
| Terminally Ill | 1 | 2000 | 240 | 0.010 |
Why?
|
| Heart | 1 | 2011 | 4449 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24318 | 0.010 |
Why?
|
| Ploidies | 1 | 1998 | 287 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2003 | 1139 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 1998 | 314 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 1995 | 9198 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 2922 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 2392 | 0.010 |
Why?
|
| Leukopenia | 2 | 1989 | 212 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2009 | 26375 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1996 | 134 | 0.010 |
Why?
|
| Cryptorchidism | 1 | 1977 | 153 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1997 | 223 | 0.010 |
Why?
|
| Hand | 1 | 2002 | 912 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 17626 | 0.010 |
Why?
|
| Subarachnoid Space | 1 | 1996 | 79 | 0.010 |
Why?
|
| DNA Probes | 1 | 1997 | 542 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 2 | 1997 | 6085 | 0.010 |
Why?
|
| Pain Measurement | 2 | 1996 | 3581 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2000 | 620 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1996 | 150 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 3955 | 0.010 |
Why?
|
| Constipation | 1 | 2000 | 570 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1995 | 397 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 23631 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2002 | 1371 | 0.010 |
Why?
|
| Germinoma | 1 | 1995 | 132 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1995 | 144 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1976 | 458 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 9261 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 18362 | 0.010 |
Why?
|
| Home Care Services | 1 | 2000 | 659 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 9682 | 0.010 |
Why?
|
| Diarrhea | 1 | 2000 | 1320 | 0.010 |
Why?
|
| Injections | 1 | 1996 | 840 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 22296 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 3922 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2003 | 5404 | 0.010 |
Why?
|
| Fatigue | 1 | 2000 | 1555 | 0.010 |
Why?
|
| Animals | 5 | 2013 | 169337 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 6510 | 0.010 |
Why?
|
| Dyspnea | 1 | 2000 | 1351 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1993 | 366 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 6670 | 0.010 |
Why?
|
| Aged | 3 | 2016 | 171562 | 0.010 |
Why?
|
| Osteoma | 1 | 1991 | 12 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1995 | 1035 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3458 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2000 | 6350 | 0.010 |
Why?
|
| Thoracotomy | 1 | 1993 | 374 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1990 | 372 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 3610 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 2106 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1990 | 228 | 0.010 |
Why?
|
| Estradiol | 1 | 1977 | 1952 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1991 | 169 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1996 | 716 | 0.010 |
Why?
|
| Urinary Tract | 1 | 1993 | 305 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2003 | 21162 | 0.010 |
Why?
|
| Trisomy | 1 | 1991 | 260 | 0.010 |
Why?
|
| Teniposide | 1 | 1989 | 11 | 0.010 |
Why?
|
| Amsacrine | 1 | 1989 | 19 | 0.010 |
Why?
|
| Keratins | 1 | 1991 | 502 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1991 | 15881 | 0.000 |
Why?
|
| Orchiectomy | 1 | 1990 | 466 | 0.000 |
Why?
|
| Factor VIII | 1 | 1991 | 349 | 0.000 |
Why?
|
| Blast Crisis | 1 | 1989 | 102 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 18048 | 0.000 |
Why?
|
| Macrophages | 1 | 1983 | 5796 | 0.000 |
Why?
|
| Incidence | 1 | 2006 | 21544 | 0.000 |
Why?
|
| Thioguanine | 1 | 1987 | 45 | 0.000 |
Why?
|
| Hematopoiesis | 1 | 1996 | 2058 | 0.000 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1992 | 494 | 0.000 |
Why?
|
| Mice | 1 | 2013 | 82017 | 0.000 |
Why?
|
| Penicillium | 1 | 1985 | 23 | 0.000 |
Why?
|
| Stomatitis | 1 | 1989 | 271 | 0.000 |
Why?
|
| Mouth Mucosa | 1 | 1989 | 437 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1993 | 1509 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1997 | 5313 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1995 | 6318 | 0.000 |
Why?
|
| Logistic Models | 1 | 2000 | 13323 | 0.000 |
Why?
|
| Body Weight | 1 | 1996 | 4629 | 0.000 |
Why?
|
| Brain | 1 | 1992 | 27454 | 0.000 |
Why?
|
| Syndrome | 1 | 1991 | 3275 | 0.000 |
Why?
|
| Liver | 2 | 1991 | 7574 | 0.000 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1989 | 687 | 0.000 |
Why?
|
| Transcriptional Activation | 1 | 1990 | 1748 | 0.000 |
Why?
|
| Aspergillosis | 1 | 1985 | 242 | 0.000 |
Why?
|
| Diploidy | 1 | 1983 | 134 | 0.000 |
Why?
|
| Metaphase | 1 | 1983 | 145 | 0.000 |
Why?
|
| Candidiasis | 1 | 1985 | 367 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 12422 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1996 | 12456 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 5857 | 0.000 |
Why?
|
| Proteins | 1 | 1976 | 6006 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 14737 | 0.000 |
Why?
|
| DNA | 1 | 1994 | 7211 | 0.000 |
Why?
|
| Kidney | 1 | 1995 | 7064 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1993 | 7599 | 0.000 |
Why?
|
| Leydig Cells | 1 | 1977 | 55 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1995 | 5443 | 0.000 |
Why?
|
| Inflammation | 1 | 1996 | 10863 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1976 | 1142 | 0.000 |
Why?
|
| Cytosol | 1 | 1977 | 886 | 0.000 |
Why?
|
| Organ Size | 1 | 1977 | 2268 | 0.000 |
Why?
|
| Rats | 2 | 1977 | 23835 | 0.000 |
Why?
|
| Kinetics | 1 | 1976 | 6333 | 0.000 |
Why?
|